Completed PHASE2 INTERVENTIONAL 1-arm NCT06603220

A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria

An Open Label Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria

Sponsor: Evommune, Inc.

Conditions Chronic Inducible Urticaria

Interventions Oral EVO756

Updated 6 times since 2024 Last updated: Jun 13, 2025 Started: Aug 14, 2024 Primary completion: May 8, 2025 Completion: May 8, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Chronic Inducible Urticaria, this trial is completed. The trial is conducted by Evommune, Inc. and has accumulated 6 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Jul 2025 — Present [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
May 2025 — Jul 2025 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Mar 2025 — May 2025 [monthly]

Recruiting PHASE2
Jan 2025 — Mar 2025 [monthly]

Recruiting PHASE2
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Oct 2024 — Dec 2024 [monthly]

Recruiting PHASE2

First recorded

Aug 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Evommune, Inc.

Data source: Evommune, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baton Rouge, United States , Bexley, United States , Birmingham, United States , Boise, United States , Fargo, United States , Indianapolis, United States , Los Angeles, United States , New Albany, United States , New York, United States , Oklahoma City, United States and 8 more locations